Between August 1994 and June 1999, 56 patients were prospectively randomized to receive ifosfamide 10 g/m 2 + GM-CSF 5 g/kg/day (IFO+GM-CSF n = 28) and cyclophosphamide 4 g/m 2 + GM-CSF 5 g/kg/day (CY+GM-CSF n = 28). Both groups were comparable for age, gender, diagnosis, disease stage and previous chemotherapy. The IFO+GM-CSF group demonstrated a shorter median interval between therapy and apheresis (10 days (8-14) vs 13 days (8-25) P = 0.002), median number of doses of GM-CSF (9 (7-13) vs 15 (9-31) P = 0.001), median of days with aplasia (0.5 (0-10) vs 6 (0-21) P = 0.001), median days with fever (0 (0-6) vs 3 (0-9) P = 0.006) and median of days using i.v. antibiotics (0 (0-11) vs 7.5 (0-19) P = 0.002). The median MNC yield was similar in both groups. The CD34 + cell yield was better in the CY+GM-CSF group (3.14 (0.9-11.8) vs 5.33 (0.08-32)) but not at significant levels (P = 0.1). White blood cell hematopoietic recovery was more rapid in the CY+GM-CSF group (16 (10-22) vs 13 (10-24) P = 0.02). Platelet engraftment was similar in both groups. Costs of mobilization and transplantation were almost the same: $28 570 ($18 527-$47 028) and $30 020 ($17 281-$67 591), respectively (P = 0.9). There were no differences in disease-free survival and overall survival between both groups. Mild and transient non-hematological toxicity (hemorrhagic cystitis, decrease in serum creatinine clearance and CNS dysfunction) was seen most frequently in the IFO+GM-CSF group. Bone Marrow Transplantation (2000) 25, 1141-1146.
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Ifosfamide is an oxazaphosphorine alkylating agent with a broad spectrum of antineoplastic activity. It is a prodrug metabolized in the liver by cytochrome P450 to isofosforamide mustard, the active alkylating compound. 12 Ifosfamide can elicit responses in patients refractory to numerous antineoplastic drugs, including cyclophosphamide. Approximately 3.5 g/m 2 of ifosfamide has equivalent antineoplastic activity to 1 g/m 2 of cyclophosphamide. 13 This drug has been used in PBPC mobilization in combination with other chemotherapy drugs 14,15 but has not been described as a single agent.
In this paper we report our single center experience with 56 randomized patients who underwent high-dose therapy utilizing PBPC collected after mobilization with high-dose ifosfamide plus GM-CSF or high-dose cyclophosphamide plus GM-CSF. We have compared the PBPC mobilization kinetics, toxicities, post-transplant hematologic engraftment and costs of mobilization and transplantation of the two different chemotherapy regimens. Overall survival and disease-free survival following HDT were also studied in these patients.
Patients and methods

Eligibility criteria
Between August 1994 and June 1999, 56 patients were prospectively randomized to receive one of the following PBPC mobilization regimens: ifosfamide 10 g/m 2 plus GM-CSF 5 g/kg/day (IFO+GM-CSF n = 28) or cyclophos- 
Patients
Patient characteristics are summarized in Table 1 . There were no differences in the median ages of the patients or disease type (non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma) between the two groups. Before mobilization, 17 cases were in complete remission and 11 had refractory disease in the IFO+GM-CSF group; 15 were in complete remission, two in first relapse and 11 had refractory disease in the CY+GM-CSF group (P = 0.3). The median number of previous chemotherapy cycles was 11 and 12 for both groups, respectively (P = 0.3). The median interval between diagnosis and mobilization chemotherapy was 21 months (6-87) for the IFO+GM-CSF group and 25 months (8-98) for the CY+GM-CSF group (P = 0.8). Four patients in each group had previously received radiotherapy.
PBPC mobilization IFO+GM-CSF: 28 patients. Ifosfamide (Ifoxan; Asta Méd-ica, Frankfurt, Germany) 10 g/m 2 i.v. infusion over 2 h, divided on 2 successive days through a central venous catheter. Hyperhydration (4 l continuous i.v. infusion over 24 h) was initiated 24 h before chemotherapy. Mesna (Uromitexan; Asta Médica) was given at 20% of the ifosfamide dosage at 0, 4 and 8 h after initiation of ifosfamide, on each of 2 successive days. RhGM-CSF (Molgramostim; Novartis/Schering Plough, Basel, Switzerland) at a dose of 5 g/kg/day subcutaneously, was started 24 h after com- pletion of chemotherapy and continued until the last leukapheresis procedure.
CY+GM-CSF:
28 patients. Cyclophosphamide (Genoxal; Asta Médica) 4 g/m 2 i.v. infusion over 2 h on 2 successive days through a central venous catheter. Hyperhydration, MESNA and GM-CSF were given at the same dose and schedule as the IFO+GM-CSF group.
All patients received ondansetron (Zofran; Glaxo Welcome, UK) 8 mg i.v. three times a day and were hospitalized during administration of chemotherapy and during aplasia.
Collection of PBPC and cryopreservation
Leukapheresis was started when the WBC count exceeded a level of 1.0 × 10 9 /l. The target was to collect Ͼ2 × 10 6 /kg of CD34 cells in a minimum of two and a maximum of five collections.
Harvesting was performed with a Fenwal CS 3000 Plus (Baxter Healthcare, Deerfield, IL, USA). For each leukapheresis, 10 l of blood were processed at a flow rate of 50-70 ml/min. Dimethylsulfoxide (DMSO; Sigma Chemical, St Louis, MO, USA) at 10% concentration was used as cryoprotectant. The final 100-110 ml suspension was frozen to −90°C and transferred into liquid-phase nitrogen and stored at −196°C.
MNC determinations and quantitation of CD34
+ cells
Total cell counts and MNC determinations were performed using an automatic cell counter and manual differential count was also performed. The numbers of CD34 + cells in the leukapheresis product at the time of collection and after thawing were enumerated by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA) using direct CD34 immunofluorescence.
Costs
Total costs of both the mobilization and the transplant procedures were calculated according to our hospital charges (national health insurance) and obtained from the finance department. Costs were calculated for each patient group and given as a median per patient. We included in this analysis: days in hospital, apheresis and blood products, chemotherapy, i.v. antibiotics, GM-CSF doses, surgery and total parenteral nutrition (TPN) and laboratory and radiology studies. Costs are given in American dollars.
High-dose therapy conditioning regimen and intensive care post transplant
The ablative treatment consisted of BEAC regimen (BCNU 450 mg/m 2 , etoposide 1600 mg/m 2 , Ara-C 1600 mg/m 2 and cyclophosphamide 140 mg/kg) in 22 and 20 patients of both groups, respectively. BEAM regimen (BCNU, etoposide and Ara-C at the same doses, and melphalan 140 mg/m 2 ) was used in six and eight patients of the IFO+GM-CSF and CY+GM-CSF groups, respectively. The patients received prophylactic bowel decontamination and antibiotic combi-nation therapy was administered for fever Ͼ38.5°C, while fluconazole (Diflucan; Pfizer, New York, NY, USA) was given for systemic fungal prophylaxis. Patients did not receive hematopoietic growth factors following high-dose therapy.
Statistical analysis
Numeric and string variables were evaluated according to standard statistical methods using a commercially available computer program (SPSS for Windows, version 8). Differences in hematological parameters and patient characteristics were evaluated using the Mann-Whitney U test for independent samples. String variables were analyzed using the 2 test. The correlation between both groups of mobilization and dependent variables was analyzed using a logistic regression model. Overall survival and disease-free survival were estimated from the day of transplantation until last follow-up or relapse respectively. A P value of Ͻ0.05 was considered significant.
Results
Leukapheresis, mononuclear cell and CD-34
+ yield
The efficacy of the two mobilization regimens is shown in Table 2 .
The median interval between the last day of mobilization chemotherapy and the first apheresis was 10 days (8) (9) (10) (11) (12) (13) (14) for the IFO+GM-CSF group and 13 days (8-25) for the CY+GM-CSF group (P = 0.002). GM-CSF was administered for a median of 9 days (7-13) and 15 days (9-31), respectively (P = 0.001). The number of aphereses performed in each group was 3 (1-4) and 3 (2-6), respectively (P = 0.1). The median number of days with ANC Ͻ0.5 × 10 9 /l was 0.5 (0-10) for the IFO+GM-CSF group Table 2 Results in peripheral blood progenitor cells mobilization Bone Marrow Transplantation and 6 (0-21) for the CY+GM-CSF group (P = 0.001). The median number of days with fever was 0 (0-6) and 3 (0-9) for both groups, respectively (P = 0.006). Systemic antibiotic treatment during mobilization was necessary for a median of 0 days (0-11) and 7.5 days (0-19), respectively (P = 0.002). There were no differences between the groups in blood product requirements. The median number of MNC was similar in both groups i.e. 3 × 10 8 /kg (0.5-21) and 3.1 × 10 8 /kg (0.5-13) (P = 0.3). There was a trend for patients receiving CY+GM-CSF to achieve higher CD34 + cell yields (5.33 × 10 6 /kg (0.08-32)) than patients receiving IFO+GM-CSF 3.14 × 10 6 /kg (0.9-11.8)) but not at a statistically significant level (P = 0.1). Four patients (14%) in the IFO+GM-CSF group and three patients (11%) in the CY+GM-CSF group did not achieve the target level of Ͼ2 × 10 6 CD34 + cells/kg. A logistic regression model showed a correlation between IFO+GM-CSF mobilization treatment and fewer days of systemic antibiotic use (P = 0.04), fewer days with aplasia (P = 0.01), fewer days with fever (0.05), fewer days utilizing GM-CSF (P = 0.0003) and fewer days between chemotherapy and apheresis (P = 0.0005). The costs of mobilization and BMT of both regimens are shown in Table 3 . In total costs, IFO+GM-CSF was cheaper than CY+GM-CSF ($28 570 ($18 527-$47 028) vs $30 420 ($17 281-$67 591)), saving a median of $1850, but this difference was not statistically significant (P = 0.9). There were no differences between both groups in post-transplant charges for i.v. antibiotics or blood products.
Engraftment kinetics after autologous transplantation are shown in Table 4 . Engraftment was not evaluable in three patients in the IFO+GM-CSF group and two patients in the CY+GM-CSF group due to early transplant-related mortality. After PBPC infusion, the median time to neutrophil (Ͼ0.5 × 10 9 /l) engraftment was 16 days (10-22) for the IFO+GM-CSF group and 13 (10-24) for the CY+GM-CSF group (P = 0.02). The median time to platelet engraftment (Ͼ20 × 10 9 /l) was 17 days (11-33) and 15 days (7-41), respectively (P = 0.9). With a median follow-up of 30 months, the disease-free survival (29 and 24 months) ( Figure 1 ) and overall survival (42 and 38 months) ( Figure 2) were not significantly different between the IFO+GM-CSF and CY+GM-CSF groups. Table 5 shows non-hematological toxicity after mobilization. Grade I-II (WHO) nausea and vomiting was present in six (21%) and five (18%) patients of the IFO+GM-CSF and CY+GM-CSF groups. Grade I (microscopic) hemorrhagic cystitis was observed in five (18%) and two (5%) patients in both groups. Grade I neurologic complaints and grade II acute renal failure occurred in five (18%) and two (5%) patients in the IFO+GM-CSF group. All these complications were mild and reversible within 24-48 h in all cases.
Mobilization regimen toxicity
Discussion
For over 15 years, it has been known that high-dose cyclophosphamide produces an increase in the reconstitutive capacity of progenitor blood cells collected during the rebound recovery phase 9 but the toxicity (mainly aplasia and infection) is considerable. By administering hematopoietic growth factors, the quantity of PBPCs increases (8.4-fold increase in CFU-GM 16 ) and hematological toxicity is reduced. A frequently used combination for PBPC mobilization is cyclophosphamide at doses ranging from 4 to 7 g/m 2 . Goldschmidt et al 10 have compared the dose of cyclophosphamide at 4 g/m 2 vs 7 g/m 2 plus G-CSF in mul- tiple myeloma patients. They found that administration of 7 g/m 2 resulted in statistically significantly higher levels of CD34 + progenitor cells. On the other hand, Alegre et al 11 have used the drug at 4 g/m 2 combined with GM-CSF with similar results. Using cyclophosphamide + GM-CSF, we can obtain up to a 1000-fold increase in CFU-GM or CD34 + cells. 17 Ifosfamide is an oxazophosphorine alkylating agent with a broad spectrum of antineoplastic activity. It is an analog of cyclophosphamide with translocation of a chlorethyl 1145 Table 5 Non-hematological toxicity after mobilization ; WHO = World Health Organization toxicity grading system. group which provides a more effective DNA cross-linking distance between two independent functional alkylating moieties. 18 Preclinical studies demonstrated differences in alkylation kinetics between the two active metabolites: phosphoramide mustard (for cyclophosphamide) and isofosforamide mustard (for ifosfamide), resulting in a longer survival of isofosforamide mustard within the cell cytoplasm and an increased probability of reaching the nucleus and alkylating DNA. 19 Ifosfamide has been used in different PBPC mobilization methods at doses ranging from 4 to 6 g/m 2 but always in combination with other chemotherapy agents and administered for 3-5 days. 14, 15 In the present study, our data shows that IFO+GM-CSF and CY+GM-CSF are both effective regimens for PBPC mobilization, even in heavily pretreated patients (most of the patients had received more than 10 cycles of chemotherapy before mobilization). During the mobilization phase our patients treated with IFO+GM-CSF had: (1) earlier mobilization, (2) fewer days treated with GM-CSF, (3) fewer days of aplasia and consequently fewer days with fever and antibiotics. On the other hand, we obtained a higher CD34
WHO
+ cell yield in the group receiving CY+GM-CSF but not at statistically significant levels. This resulted in a more rapid WBC engraftment but similar numbers of days in hospital and days on i.v. antibiotics. Eleven patients in each group underwent transplantation in a refractory phase and they had been heavily treated before. This could be one reason to explain the poor CD34 + yields obtained from some patients, not only in the IFO+GM-CSF group, but also in the CY+GM-CSF group. Throughout mobilization and transplant procedures, the IFO+GM-CSF regimen saved a median of $1850 dollars per patient because of a favorable balance in costs due to fewer doses of GM-CSF and fewer days in hospital during the mobilization phase, although this difference was not statistically significant. Disease-free survival and overall survival were almost the same in both groups.
Mild and reversible non-hematological toxicity, mainly hemorrhagic cystitis, acute renal failure and CNS toxicity was more common in the IFO-GM-CSF group. Ifosfamide has been associated with significant CNS toxicity with an incidence of 12-22%. This complication may be related to high serum levels of chloracetaldehyde, one of the major metabolites of the drug and may occur when the drug is used at standard as well as higher doses. 20 The onset of symptoms is variable and may occur within 2 h of administration of a bolus dose or might not appear until 28 days Bone Marrow Transplantation after therapy. Clinical manifestations consist of mental status changes, cerebellar dysfunction, urinary incontinence, motor system dysfunction, cranial nerve dysfunction and in severe cases seizures, encephalopathy and coma. Fortunately, as in our series, all these clinical manifestations resolved within 3 days of stopping the infusion. 21 Watkin et al 22 reported CNS toxicity in 18 out of 82 (22%) patients treated with ifosfamide. In our study, we observed SNC disturbances in five out of 28 patients (18%), predominantly confusion and auditory or visual hallucinations. We did not observe urinary incontinence or severe toxicity, the symptoms were mild and resolved completely within 24 h of the last dose of ifosfamide, without the use of methylene blue or bicarbonate infusions.
In conclusion, IFO+GM-CSF and CY+GM-CSF are both useful PBPC mobilization regimens. The ifosfamide regimen offers some advantages during the mobilization phase such as a brief period of aplasia, a short interval between chemotherapy and first apheresis, fewer days using GM-CSF, lower incidence of infections, fewer febrile episodes and fewer days using antibiotics. However, the CD34 + cell yield is slightly better with CY+GM-CSF but this is not statistically significant. Disease-free survival and overall survival after autologous PBPC transplantation is the same in both groups. Non-hematological toxicity, mainly CNS toxicity, hemorrhagic cystitis and acute renal failure are more frequent using IFO+GM-CSF but these toxicities are mild and rapidly reversible. To our knowledge, this is the first study using ifosfamide as a single chemotherapy agent in combination with GM-CSF for PBPC mobilization. Because we obtained similar results with cyclophosphamide, we think ifosfamide is an alternative for patients already heavily pretreated with cyclophosphamide.
